Bupropion for attention deficit hyperactivity and comorbid disorders

Expert Review of Neurotherapeutics

Volumn 3, Issue 1, 2003, Pages 9-18

  Daviss, W Burleson ^a   Pan, Raymond J ^a   Perel, James M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Anxiety; Attention deficit hyperactivity disorder; Bipolar; Bupropion; Comorbid; Depression; Dopaminergic; Noradrenergic; Substance abuse

Indexed keywords

AMFEBUTAMONE;

ANXIETY NEUROSIS; ATTENTION DEFICIT DISORDER; BLOOD SAMPLING; COMORBIDITY; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FIRST PASS EFFECT; HUMAN; REVIEW; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION;

EID: 0037224763     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.1.9     Document Type: Review

References (87)

1. Feighner JP, Meredith CH, Stern WC, Hendrickson G, Miller LL. A double-blind study of bupropion and placebo in depression. Am. J. Psychiatry 141(4), 525-529 (1984).
2. Lineberry CG, Johnston JA, Raymond RN et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed out-patients. J. Clin. Psychiatry 51(5), 194-199 (1990).
3. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed out-patients. Clin. Therapeutics Int. J. Drug Therapy 20(3), 505-516 (1998).
4. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed out-patients. J. Clin. Psychiatry 58(12), 532-537 (1997).
5. Weihs KL, Settle EC Jr, Batey SR et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry 61(3), 196-202 (2000).
6. Coleman CC, Cunningham LA, Foster VJ et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann. Clin. Psychiatry 11(4), 205-215 (1999).
7. Feighner JP, Gardner EA, Johnston JA et al. Double-blind comparison of bupropion and fluoxetine in depressed out-patients. J. Clin. Psychiatry 52(8), 329-335 (1991).
8. Anonymous. Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. Ann. Intern. Med 135(6), S-40 (2001).
9. Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann. Intern. Med 135(6), 423-433 (2001).
10. Hurt RD, Sachs DP, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med 337(17), 1195-1202 (1997).
11. Ascher JA, Cole JO, Colin JN et al. Bupropion: A review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56(9), 395-401 (1995). Good review article about bupropion's pharmacodynamic effects.
12. Cooper BR, Wang CM, Cox RF et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacolagy 11, 133-141 (1994).
13. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J. Affect. Disorders 51(3), 237-254 (1998).
14. Hesse LM, Venkatakrishnan K, Court MH et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metabolism Disposition 28(10), 1176-1183 (2000).
15. Goodnick PJ. Pharmacokinetics of second generation antidepressants: Bupropion. Psychopharmacol. Bull. 27(4), 513-519 (1991).
16. Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ. Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23(4), 187-194 (1990).
17. Perumal AS, Smith TM, Suckow RF, Cooper TB. Effect of plasma from patients containing bupropion and its metabolites on the uptake of noradrenaline. Neuropharmacology 25(2), 199-202 (1986).
18. Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression: I. Biochemical effects and clinical response. Arch. Gen. Psychiatry 45(2), 139-143 (1988).
19. Preskorn SH. Antidepressant response and plasma concentrations of bupropion. J. Clin. Psychiatry 44, 137-139 (1983).
20. Preskorn SH, Katz SE. Bupropion plasma levels: Intraindividual and interindividual variability. Ann. Clin. Psychiatry 1(1), 59-61 (1989).
21. Casat CD, Pleasants DZ, Schroeder DH, Parler DW. Bupropion in children with attention deficit disorder. Psychopharmacol. Bull. 25(2), 198-201 (1989).
22. Simeon JG, Ferguson HB, Van Wyck Fleet J. Bupropion effects in attention deficit and conduct disorders. Can. J. Psychiatry Revue Canadienne de Psychiatrie 31(6), 581-585 (1986).
23. Golden RN, DeVane CL, Laizure SC et al. Bupropion in depression: II. The role of metabolites in clinical outcome. Arch. Gen. Psychiatry 45(2), 145-149 (1988).
24. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: Results of three clinical trials. Clin. Therapeutics Int. J. Drug Therapy 21(3), 454-463 (1999).
25. Settle EC. Bupropion sustained release: side effect profile. J. Clin. Psychiatry 4, 32-36 (1998). Good review about the relative tolerability of bupropion's SR and IR forms.
26. Davidson J. Seizures and bupropion: a review. J. Clin. Psychiatry 50(7), 256-261 (1989).
27. GlaxoSmithKline I. Product Information: Wellbutrin SR (bupropion hydrochloride) sustained-release tablets. Information on File, 1-22 (2000).
28. Dunner DL, Zisook S, Billow AA et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J. Clin. Psychiatry 59(7), 366-373 (1998).
29. Brown ES, Dilsaver SC, Shoaib AM, Swann AC. Depressive mania: response of residual depression to bupropion. Biol. Psychiatry 35(7), 493-494 (1994).
30. Goren JL, Levin GM. Mania with bupropion: a dose-related phenomenon? Ann. Pharmacother. 34(5), 619-621 (2000).
31. Masand P, Stern TA. Bupropion and secondary mania. Is there a relationship? Ann. Clin. Psychiatry 5(4), 271-274 (1993).
32. Zubieta JK, Demitrack MA. Possible bupropion precipitation of mania and a mixed affective state. J. Clin. Psychopharmacology 11(5), 327-328 (1991).
33. Stoll AL, Mayer PV, Kolbrener M et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am. J. Psychiatry 151(11), 1642-1645 (1994).
34. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL The Expert Consensus Guidelines for treating depression in bipolar disorder. J. Clin. Psychiatry 59(Suppl. 4), 73-79 (1998).
35. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol. Psychiatry 48(6), 558-572 (2000).
36. Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. Ann. Pharmacotherapy 27(4), 431-433 (1993).
37. Barrickman LL, Perry PJ, Allen AJ et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad Child Adolesc. Psychiatry 34(5), 649-657 (1995).
38. Conners CK, Casat CD, Gualtieri CT et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J. Am. Acad Child Adolesc. Psychiatry 35(10), 1314-1321 (1996).
39. Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ. Bupropion SR in the treatment of adolescent depression. In: Child Section of the 40th Annual National Institutes of Mental Health New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, USA, May 30-June 2 (2000).
40. Daviss WB, Bentivoglio P, Racusin R et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J. Am. Acad. Child Adolesc. Psychiatry 40(3), 307-314 (2001).
41. Spencer T, Biederman J, Steingard R, Wilens T. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J. Am Acad. Child Adolesc. Psychiatry 32(1), 211-214 (1993).
42. Jacobsen LK, Chappell P, Woolston JL. Bupropion and compulsive behavior. J. Am. Acad. Child Adolesc. Psychiatry 33(1), 143-144 (1994).
43. Branch RA. Characteristics of drug disposition during childhood. In: Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disorders. Gershon S (Ed.). Brunner/Mazel Publishers, New York, NY, USA (1994).
44. Posner J, Bye A, Dean K, Peck AW, Whiteman PD. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur. J. Clin Pharmacology 29(1), 97-103 (1985).
45. Daviss WB, Perel J, Rudolph G et al. Pharmacokinetics of bupropion SR in adolescent patients. In: 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, USA, October 22-27 (2002).
46. Sweet RA, Pollock BG, Kirshner Metal. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J. Clin. Pharmacology 35(9), 876-884 (1995).
47. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metabolism Disposition 29(2), 100-102 (2001).
48. Nemeroff CB, DeVane CL, Pollock BG. New antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153, 311-320 (1996).
49. Ketter TA, Jenkins JB, Schroeder DH et al. Carbamazepine but not valproate induces bupropion metabolism. J. Clin. Psychopharmacology 15(5), 327-333 (1995). Good general review article about the epidemiology, assessment, treatment and course of ADHD in children and adolescents.
50. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am. Acad. Child Adolesc. Psychiatry 35(8), 978-987 (1996). Summarizes literature about the role of catecholamines in the pathophysiology of ADHD.
51. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J. Am Acad Child Adolesc. Psychiatry 35(3), 264-272 (1996). Excellent review article summarizing the range of pharmacological treatments for ADHD and their level of empirical support.
52. Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad Child Adolesc. Psychiatry 35(4), 409-432 (1996). Reviews empirical support for bupropion for ADHD across lifespan.
53. Cantwell DP. ADHD through the lifespan: the role of bupropion in treatment. J. Clin. Psychiatry 59(Suppl. 4), 92-94 (1998).
54. Wilens TE, Spencer TJ, Biederman J et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am. J. Psychiatry 158(2), 282-288 (2001). Good review article about ADHD comorbidity, with some practical clinical suggestions.
55. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J. Clin. Psychiatry 59(Suppl. 7), 50-58 (1998). Another good review article about ADHD comorbidity.
56. Spencer T, Biederman J, Wilens T Attention-deficit/hyperactivity disorder and comorbidity. Pediatric Clin. N. Am. 46(5), 915-927 (1999). Reviews ADHD comorbidity from the standpoint of unanswered empirical questions.
57. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice and DSM-V. J. Am. Acad Child Adolesc. Psychiatry 36(8), 1065-1079 (1997).
58. Biederman J, Faraone SV, Keenan K et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch. Gen. Psychiatry 49(9), 728-738 (1992).
59. Biederman J, Faraone S, Mick E, Moore P, Lelon E. Child Behavior Checklist findings further support comorbidity between ADHD and major depression in a referred sample. J. Am. Acad. Child Adolesc. Psychiatry 35(6), 734-742 (1996).
60. Birmaher B, Ryan ND, Williamson DE et al. Childhood and adolescent depression: A review of the past 10 years, Part I. J. Am Acad. Child Adolesc. Psychiatry 35(11), 1427-1439 (1996).
61. Biederman J. Attention-deficit/hyperactivity disorder: a lifespan perspective. J. Clin. Psychiatry 59(Suppl. 7), 4-16 (1998).
62. Zomberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J. Clin. Psychopharmacology 13(6), 397-408 (1993).
63. Wilens T, Prince J, Spencer T et al. Bupropion SR for ADHD in adults with bipolar disorder and ADHD: preliminary data. In: The 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, USA, October 24-29 (2000).
64. Goodnick PJ, Dominguez RA, DeVane CL, Bowden CL. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol. Psychiatry 44(7), 629-632 (1998).
65. Pliszka SR. Effect of anxiety on cognition, behavior and stimulant response in ADHD. J. Am. Acad. Child Adolesc. Psychiatry 28(6), 882-887 (1989).
66. Trivedi MH, Rush AJ, Carmody TJ. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J. Clin. Psychiatry 62(10), 776-781 (2001).
67. Rush AJ, Trivedi MH, Carmody TJ et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 25(1), 131-138 (2001).
68. Rush AJ, Batey SR, Donahue RM et al. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J. Affect. Disorders 64(1), 81-87 (2001).
69. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J. Clin. Psychopharmacology 3(1), 28-31 (1983).
70. Emmanuel NP, Pollack MH, Morton A et al. Bupropion sustained release in the treatment of panic disorder. In: Poster presented at the New Clinical Drug Evaluation Unit Program (NCDEU, Boca Raton, FL, USA, June 10-13 (2001).
71. Emmanuel NE, Brawman-Mintzer O, Morton WA et al. Bupropion-SR in treatment of social phobia. Depression Anxiety 12(2), 111-113 (2000).
72. Canive JM, Clark RD, Calais LA, Qualls C, Tuason VB. Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J. Clin. Psychopharmacology 18(5), 379-383 (1998).
73. Almai AM, Brouette T, Jetty P et al. Bupropion sustained release in the treatment of civilian post traumatic stress disorder. In: Poster Presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, USA, May 13-18 (2000).
74. Nutt DJ. Addiction: brain mechanisms and their treatment implications. Lancet 347(8993), 31-36 (1996).
75. Robbins TW, Granon S, Muir JL et al. Neural systems underlying arousal and attention. Implications for drug abuse. Ann. NYAcad. Sci. 846, 222-237 (1998).
76. Solhkhan R, Wilens T, Prince J. Bupropion substained release for substance abuse, ADHD and mood disorders in adolescents. In: Poster Presented at the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA, May 5-10 (2001).
77. Margolin A, Kosten T, Petrakis I, Avants SK. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch. Gen. Psychiatry 48(1), 87 (1991).
78. Margolin A, Kosten TR, Avants SK et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Dependence 40(2), 125-131 (1995). First of two papers developed by the consensus panel of experts with the Texas Medical Algorithms Project, this paper provides treatment algorithms and their empirical support in the pharmacological management of ADHD and it comorbid conditions, including major depression/anxiety; tics and intermittent explosive disorders.
79. Pliszka SR, Greenhill LL, Crimson ML et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. J. Am. Acad Child Adolesc. Psychiatry 39(7), 908-919 (2000).
80. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J. Child Adolesc. Psychopharmacology 3(1), 1-10 (1993).
81. Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin re-uptake inhibitors and psychostimulants in children, adolescents and adults: a case series. J. Child Adolesc. Psychopharmacology 6(3), 165-175 (1996).
82. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5), E83 (2001).
83. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafixine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J. Child Adolesc. Psychopharmacology 6(4), 241-250 (1996).
84. Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 54(11), 1031-1037 (1997).
85. Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 40(7), 762-772 (2001).
86. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J. Clin. Psychiatry 59(Suppl. 18), 23-29 (1998).
87. Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin. Psychiatry 59(Suppl. 4), 5-14 (1998).